Supernus Pharma Revenue, Profits - SUPN Annual Income Statement

Add to My Stocks
$49.9 $2 (4.18%) SUPN stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the Supernus Pharma stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $302.23M for 2017 impacts the SUPN stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Supernus Pharma profit and loss statement for 2017 total to $187.47M. This line item shows that the operating expenses has increased compared with last year. Also check: Supernus Pharma assets and Supernus Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec20172016201520142013201220112010
Supernus Pharma Revenues or Net Sales
302.23M215M144.42M122.04M12.01M1.48M--
Cost Of Goods Sold (COGS)15.21M11.98M8.42M5.75M1.1M---
Supernus Pharma Gross Profit
287.02M203.01M136M116.28M10.91M1.48M--
Research & Development Expense49.57M42.79M29.13M19.58M17.24M23.51M30.62M35.14M
Selling General & Admin Expense137.9M106.01M89.2M72.47M55.59M20.13M7.92M5.08M
Income Before Depreciation Depletion Amortization99.54M54.21M17.66M24.23M-61.92M-42.16M-37.75M-40.12M
Depreciation Depletion Amortization--------
Non Operating Income2.64M1.24M-1.46M--22.5M-0.54M--
Interest Expense1.56M5.09M1.22M4.96M7.84M3.57M1.86M-
Supernus Pharma Pretax Income
100.61M50.36M14.97M19.87M-92.27M-46.28M-39.47M-39.47M
Provision for Income Taxes43.33M-40.85M-----16.24M-0.39M
MinorityInterest--------
Investment Gains Losses--------
Other Income--------
Income Before Extraordinaries & Disc Operations57.28M91.22M14.01M19.87M-92.27M-46.28M-23.22M-39.07M
Extraordinary Items & Discontinued Operations------77.04M-
Supernus Pharma Profit/ Loss (Net Income)
57.28M91.22M14.01M19.87M-92.27M-46.28M53.81M-38.46M
Average Shares used to compute Diluted EPS53.3M51.71M51.16M50.58M31.85M17.44M1.61M-
Average Shares used to compute Basic EPS50.76M49.47M47.49M42.26M31.85M17.44M1.61M-
Income Before Nonrecurring Items66.98M50.37M15.54M-10.35M-69.37M-47.43M-23.23M-
Income from Nonrecurring Items-9.69M40.85M-1.52M30.22M-22.9M---
Supernus Pharma Earnings Per Share Basic Net
1.131.840.300.47-2.90-2.7231.39-
Supernus Pharma Earnings Per Share Diluted Net
1.081.760.280.32-2.90-2.7231.39-
EPS Diluted Before Nonrecurring Items1.260.950.31-0.24-2.18-2.72-16.60-
Preferred Dividends Acc Pd--------
Dividends Common--------
Dividend Per Share Common0.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Supernus Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that SUPN stock has a topline or revenue of $302.23M for 2017 as per this Supernus Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $57.28M for Supernus Pharma for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the SUPN income statement, one can check the Supernus Pharma historical stock prices to check how the price has moved with time.

Supernus Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
29.75
PS Ratio (price sales ratio)
6.93
Operating Margin
35.9
Net Profit Margin
30.9
Dividend Yield
0%